Drugs / NMS-03305293
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06930755 | May 2026 → May 2027 expected | ovarian cancer | Nerviano Medical Sciences | Recruiting | No outcome recorded |
| Phase 1 | NCT06931626 | Aug 2025 → Oct 2026 expected | small cell lung carcinoma | Nerviano Medical Sciences | Recruiting | No outcome recorded |
| Phase 1 | NCT04182516 | Nov 2019 → Mar 2023 | — | Nerviano Medical Sciences | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04910022 | Dec 2021 → May 2027 expected | glioblastoma | Nerviano Medical Sciences | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-01-13 | Nerviano Medical Sciences | Regulatory Nerviano Medical Sciences announces FDA clearance of two INDs for its PARP1-selective, non-trapping inhibitor NMS-293 to start clinical studies in small cell lung cancer and BRCA wild-type ovarian carcinoma nervianoms.com ↗
Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS, a global leader in oncological innovation, are pleased to announce that the U.S. Food and Drug Administration (FDA) has granted approval to proceed with two clinical studies in the relapse setting for small cell lung cancer and BRCA wild-type ovarian cancer. |
| 2023-10-12 | Nerviano Medical Sciences | Results Nerviano Medical Sciences S.r.l. to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC 2023: Poster nervianoms.com ↗
Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, reported today, initial results from the dose escalation parts of two Phase I-I/II studies for NMS-03305293 (NMS-293). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-01-13 | Nerviano Medical Sciences | Nerviano Medical Sciences announces FDA clearance of two INDs for its PARP1-selective, non-trapping inhibitor NMS-293 to start clinical studies in small cell lung cancer and BRCA wild-type ovarian carcinoma nervianoms.com ↗ |
| 2023-10-12 | Nerviano Medical Sciences | Nerviano Medical Sciences S.r.l. to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC 2023: Poster nervianoms.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NMS-03305293 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04910022 ↗ |
| Action | Inhibit | “NMS-03305293 (a PARP inhibitor)” NCT04182516 ↗ |
| Route | Oral | “NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.” NCT04182516 ↗ |
| Target | PARP1 | “NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor” NCT06930755 ↗ |